2025
Assessment of ctDNA somatic homologous recombination deficiency (HRD) in triple-negative breast cancer (TNBC) from SWOG S1416 trial.
Stecklein S, Barlow W, Tsai J, Yablonovitch A, Rodler E, Kuhn P, Hicks J, Pathak H, Hayes D, Rae J, Hortobagyi G, Thompson A, Godwin A, Pusztai L, Sharma P. Assessment of ctDNA somatic homologous recombination deficiency (HRD) in triple-negative breast cancer (TNBC) from SWOG S1416 trial. Journal Of Clinical Oncology 2025, 43: 1012-1012. DOI: 10.1200/jco.2025.43.16_suppl.1012.Peer-Reviewed Original ResearchTriple-negative breast cancerHomologous recombination deficiencyProgression-free survivalMetastatic TNBCWildtype patientsMetastatic triple-negative breast cancerHomologous recombination deficiency phenotypePre-treatment blood samplesDetect somatic alterationsPredictive of benefitDNA-damaging chemotherapyEvaluated pre-treatmentGBRCA mutationRecombination deficiencyPARP inhibitorsSomatic alterationsGBRCABRCABreast cancerGene panelPathway alterationsVeliparibHomologous recombination repairBiomarker panelAssociated with benefits
2021
The impact of prior therapies on outcomes with trifluridine/tipiracil (FTD/TPI) in the phase III TAGS trial.
Shitara K, George B, Taieb J, Sundar R, Fakih M, Makris L, Benhadji K, Ghidini M. The impact of prior therapies on outcomes with trifluridine/tipiracil (FTD/TPI) in the phase III TAGS trial. Journal Of Clinical Oncology 2021, 39: 247-247. DOI: 10.1200/jco.2021.39.3_suppl.247.Peer-Reviewed Original ResearchFTD/TPI treatmentSafety profileAdverse eventsSafety of FTD/TPIGastroesophageal junction cancerThird-line chemotherapySecond-line treatmentPost Hoc AnalysisHematologic toxicityOS benefitChemotherapy regimensJunction cancerSurvival benefitEfficacy benefitsFTD/TPIRamucirumabTagging trialsPlaceboPaclitaxelPrior treatmentAssociated with benefitsHoc AnalysisInfluence outcomesChemotherapySubgroup A
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply